Medi-Maa (Macrosalb (99mtc))

• Medi-Maa (Macrosalb) is used in nuclear medicine to provide radiotracer imaging for several clinical pathways.
• Oncologic imaging: enables visualization of malignant lesions during PET/CT scans, aiding tumor detection and staging.
• Cardiac imaging: facilitates assessment of myocardial perfusion in nuclear stress tests, supporting evaluation of coronary artery disease.
• Renal imaging: aids in evaluation of renal perfusion and function, assisting in the assessment of kidney disorders.

• Macrosalb is a radiolabeled compound that emits gamma photons detectable by PET or SPECT cameras. After intravenous injection, it distributes according to physiological pathways and binds to specific cellular targets or is taken up by organs of interest. The emitted radiation is captured to generate high‑resolution images that reflect tissue metabolism, perfusion, or receptor expression, thereby providing functional information complementary to anatomical imaging.

Medi-Maa may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild discomfort at the infusion site.
• Nausea: transient feeling of queasiness.
• Headache: mild to moderate headache.
• Flushing: temporary warmth or redness of skin.
• Fatigue: short‑term tiredness.
• Mild rash: limited skin irritation.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure post‑injection.
• Radiation‑induced tissue injury: localized damage from high radiation dose.
• Organ toxicity: impaired renal or hepatic function.
• Severe skin reaction: extensive dermatitis or ulceration.
• Hematologic abnormalities: significant drop in blood cell counts.

• Prior to administering Medi-Maa, clinicians should observe several precautionary measures to ensure patient safety.
• Patient assessment: evaluate renal and hepatic function before injection.
• Pregnancy: avoid use in pregnant women unless the diagnostic benefit outweighs risk.
• Breastfeeding: discontinue nursing for an appropriate period after administration.
• Medication review: assess concurrent drugs that may alter radiotracer distribution.
• Allergy history: confirm no prior hypersensitivity to radiopharmaceuticals.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medi-Maa can interact with certain agents that may affect its distribution, imaging quality, or safety profile.

Major Interactions (Avoid)

• Iodine‑containing contrast agents: can compete for uptake and reduce image quality.
• High‑dose chemotherapeutic agents: may increase bone‑marrow toxicity when combined.
• Thyroid hormone therapy: may alter tracer biodistribution in thyroid tissue.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: can modify cardiac perfusion imaging results.
• Diuretics: may affect renal tracer clearance and interpretation.
• Antihistamines: could mask mild allergic reactions to the radiopharmaceutical.